Zhen Su
CIK: 0001991642
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jun 17, 2026CTMX
CytomX Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
59K shares- - May 21, 2026KPTI
Karyopharm Therapeutics Inc.
Award(A)Direct15.5K shares- - Jun 11, 2025CTMX
CytomX Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
38K shares- - May 28, 2025KPTI
Karyopharm Therapeutics Inc.
Award(A)DirectNonstatutory Stock Option (right to buy)
4.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 17, 2026 |  CTMX CytomX Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 59,000 | - | - | Direct |
| May 21, 2026 |  KPTI Karyopharm Therapeutics Inc. | Award(A) | 15,508 | - | $0 | Direct |
| Jun 11, 2025 | CTMX CytomX Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 38,000 | - | - | Direct |
| May 28, 2025 | KPTI Karyopharm Therapeutics Inc. | Award(A) Nonstatutory Stock Option (right to buy) | 4,600 | - | - | Direct |
1-4 of 4 transactions
About Su Zhen
Su Zhen (SEC CIK 0001991642) files insider reports with the SEC as Director of CytomX Therapeutics, Inc. (CTMX) and Director of Karyopharm Therapeutics Inc. (KPTI).
Signal8 holds 4 ownership filings by Su Zhen, all Form 4s, filed between May 29, 2025 and Jun 22, 2026. Those filings report 4 transactions, from May 28, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Su Zhen's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Su Zhen
Other insiders filing for CytomX Therapeutics, Inc. (CTMX)
- McCarthy Sean A., CEO
- Carvajal Alejandra, Chief Legal Officer
- Fuchs Charles S., Director
- Young Matthew P., Director
- Mohindru Mani, Director
- Meyers James R, Director